1-5 of 5
Mariano Ponz-Sarvise
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

Pasi A. Jänne, Frédéric Bigot, Kyriakos Papadopoulos, Lauriane Eberst, David Sommerhalder, Loic Lebellec, Pei Jye Voon, Bruna Pellini, Ewa Kalinka, Kathryn Arbour, Benjamin Herzberg, Valentina Boni, Stephanie Bordenave, Hyun Woo Lee, Sai I. Ou, Jonathan Wesley Riess, Joseph T. Beck, Mariano Ponz-Sarvise, Paolo Antonio Ascierto, Yoon Ji Choi, Michelle Yang, Lei Bao, Rakesh Raman, Luxi Yang, Yunming Mu, Sofia Wong, Richa Dua, Melissa Johnson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): PR014.
https://doi.org/10.1158/1535-7163.TARG-23-PR014
Published: 01 December 2023
View article titled, Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRAS<sup>G12C</sup>(ON) inhibitor, in patients with or without prior KRAS<sup>G12C</sup>(OFF) inhibitor treatment
Journal Articles

Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study

Alison M Schram, Vivek Subbiah, Chih-Yi (Andy) Liao, Victor Moreno, Roda Desamparados, Mariano Ponz-Sarvise, Efrat Dotan, Philippe Alexandre Cassier, Irene Moreno, Andreas Varkaris, Richard D Kim, Elena Garralda, Frans Opdam, David Tai, Antoine Italiano, Do-Youn Oh, Lipika Goyal, Elisa Fontana, Jia Liu, Myrto Boukovala, Francois Ghiringelli, Mitesh J Borad, Hani Babiker, Zhaohui Jin, Michael Millward, Jeffrey Yachnin, Suneel Deepak Kamath, Jermaine M. Coward, Changhoon Yoo, Robin Kate Kelley, Vaibhav Sahai, John Bridgewater, Christoph Springfield, Vaia Florou, Anthony El-Khoueiry, Ferry Eskens, Bruce Lin, Scott Paulson, Giuseppe Curigliano, Meredith Murphy, Alicia Deary, Fabien Ricard, Kai Yu Jen, Florence (Tianhui) Ramirez, Rick E. Blakesley, Oleg Schmidt-Kittler, Brenton G. Mar, Joon Oh Park, Antoine Hollebecque
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): IA006.
https://doi.org/10.1158/1535-7163.TARG-23-IA006
Published: 01 December 2023
View article titled, Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
Journal Articles

Abstract P225: Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

David S. Hong, Daniel Catenacci, Lyudmila Bazhenova, Byoung Chul Cho, Mariano Ponz-Sarvise, Rebecca Heist, Victor Moreno, Gerald Falchook, Viola W. Zhu, Aurélie Swalduz, Benjamin Besse, Dong-Wan Kim, Shinkyo Yoon, Xiuning Le, Tingting Zhao, Alysha Kadva, Zachary Zimmerman, Jeeyun Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P225.
https://doi.org/10.1158/1535-7163.TARG-21-P225
Published: 01 December 2021
View article titled, Abstract P225: Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in <em>MET</em>: Update from the Phase 1 SHIELD-1 trial
Journal Articles

Abstract P033: CC-95775, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients with advanced solid tumors (STs): Results of a phase 1 study

Thierry Lesimple, María José de Miguel, Cristophe Le Tourneau, Mariano Ponz-Sarvise, Marie Paule Sablin, Diego Salas Benito, Bishoy Hanna, Henry Chang, Xin Wei, Marta Ocejo Garcia, Pilar Lardelli, Tania Sánchez, Josep Lluís Parra Palau, Zariana Nikolova, Emiliano Calvo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P033.
https://doi.org/10.1158/1535-7163.TARG-21-P033
Published: 01 December 2021
View article titled, Abstract P033: CC-95775, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients with advanced solid tumors (STs): Results of a phase 1 study
Journal Articles

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies

María E. Rodríguez-Ruiz, Inmaculada Rodríguez, Lina Mayorga, Tania Labiano, Benigno Barbes, Iñaki Etxeberria, Mariano Ponz-Sarvise, Arantza Azpilikueta, Elixabet Bolaños, Miguel F. Sanmamed, Pedro Berraondo, Felipe A. Calvo, Mary Helen Barcelos-Hoff, Jose L. Perez-Gracia, Ignacio Melero
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 621–631.
https://doi.org/10.1158/1535-7163.MCT-18-0558
Published: 01 March 2019
View article titled, TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Open the PDF for TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies in another window
Includes: Supplementary data